Sino Biological/TGFβ1 ELISA试剂盒，人/1/KIT10804
商品编号：
KIT10804
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
TGF beta 1 ELISA Kit, Human: General Information
Product name
TGF beta 1 ELISA Kit, Human
Assay type
Solid Phase Sandwich ELISA (quantitative)
Conjugate
HRP
Sample type
Serum
Sensitivity
23.2 pg/mL
Assay range
46.88-3000 pg/mL
Specificity
Recognizes both recombinant and natural Human TGF beta 1
Precision
| Intra-assay Precision | |||
|---|---|---|---|
| Sample | 1 | 2 | 3 |
| N | 20 | 20 | 20 |
| Mean(pg/mL) | 529.00 | 1,063.00 | 2,115.00 |
| SD | 20.14 | 64.52 | 58.67 |
| CV(%) | 3.8% | 6.1% | 2.8% |
| Inter-assay Precision | |||
| Sample | 1 | 2 | 3 |
| N | 20 | 20 | 20 |
| Mean(pg/mL) | 542.00 | 1,048.00 | 2,041.00 |
| SD | 18.36 | 16.09 | 85.22 |
| CV(%) | 3.4% | 1.5% | 4.2% |
Recovery
The recovery of Human TGFB1 spiked to different levels throughout the range of the assay in related matrices was evaluated.
| Sample |
|---|
| serum (n=3) |
| Average % Recovery |
| 84 |
| Range |
| 81 -87% |
| Sample |
| urine (n=3) |
| Average % Recovery |
| 84 |
| Range |
| 81 -87% |
Linearity
Serum
| Recovery of detected | |
|---|---|
| 1:2 | 95% |
| 1:4 | 105% |
| 1:8 | 100% |
| 1:16 | 92% |
Supernatant
| Recovery of detected | |
|---|---|
| 1:2 | 93% |
| 1:4 | 98% |
| 1:8 | 109% |
| 1:16 | 95% |
Materials provided
1. 96 well microplate coated with Capture Antibody2. Detection Antibody conjugated to HRP3. Standards4. Wash Buffer Concentrate5. Dilution Buffer Concentrate6. Color Reagent A7. Color Reagent B8. Stop Solution
Product overview
This TGF beta 1 ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human TGF beta 1 protein in Serum . It contains recombinant Human TGF beta 1, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
Shipping
This ELISA Kit is shipped at ambient temperature.
Storage
Unopened Kit: Store at 2 - 8℃Opened/Reconstituted Reagents: Please refer to CoA
TGF beta 1 ELISA Kit, Human: Images
This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
This assay recognizes both recombinant and natural Human TGFβ1. The factors listed below were prepared at 50 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.
TGF beta 1 ELISA Kit, Human: Synonyms
CED ELISA Kit, Human; DPD1 ELISA Kit, Human; LAP ELISA Kit, Human; TGF-beta 1 ELISA Kit, Human; TGFB ELISA Kit, Human; TGFbeta ELISA Kit, Human
TGF beta 1 Background Information
TGF-beta 1 is a member of the transforming growth factor beta (TGF-beta) family. The transforming growth factor-beta family of polypeptides are involved in the regulation of cellular processes, including cell division, differentiation, motility, adhesion and death. TGF-beta 1 positively and negatively regulates many other growth factors. It inhibits the secretion and activity of many other cytokines including interferon-γ, tumor necrosis factor-alpha and various interleukins. It can also decrease the expression levels of cytokine receptors. Meanwhile, TGF-beta 1 also increases the expression of certain cytokines in T cells and promotes their proliferation, particularly if the cells are immature. TGF-beta 1 also inhibits proliferation and stimulates apoptosis of B cells, and plays a role in controlling the expression of antibody, transferrin and MHC class II proteins on immature and mature B cells. As for myeloid cells, TGF-beta 1can inhibit their proliferation and prevent their production of reactive oxygen and nitrogen intermediates. However, as with other cell types, TGF-beta 1 also has the opposite effect on cells of myeloid origin. TGF-beta 1 is a multifunctional protein that controls proliferation, differentiation and other functions in many cell types. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Once cells lose their sensitivity to TGF-beta1-mediated growth inhibition, autocrine TGF-beta signaling can promote tumorigenesis. Elevated levels of TGF-beta1 are often observed in advanced carcinomas, and have been correlated with increased tumor invasiveness and disease progression.
- Cancer Immunotherapy
- Immune Checkpoint
- Immunotherapy
- Targeted Therapy
Full Name
transforming growth factor, beta 1
Research Areas
- Early Mesodermal Lineage Markers
- Cancer Drug Targets
Related Pathways
P38 MAPK Signaling Pathway
References
- Ghadami M, et al. (2000) Genetic Mapping of the Camurati-Engelmann Disease Locus to Chromosome 19q13.1-q13.3. Am J Hum. Genet. 66(1):143-7.
- Letterio J, et al. (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol. 16:137-61.
- Vaughn SP, et al. (2000) Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region. Genomics. 66(1):119-21.
- Assoian R, et al. (1983) Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 258(11):7155-60.
- Influence of Th17/Treg balance on progression of liver cirrhosis in patients with chronic hepatitis BAuthorWu, C;Dong, X;Yang, Q;Sun, Z;Year2018JournalInternational Journal of Clinical and Experimental MedicinePubMed ID: 22745730FoldedExpand
- Comparative evaluation of mesenchymal stromal cells from umbilical cord and amniotic membrane in xeno-free conditionsAuthorMu, Y;Wu, X;Hao, Z;Year2018JournalBMC Cell Biol.PubMed ID: 30545286FoldedExpand
- Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinomaAuthorSu, Q;Fan, M;Wang, J;Ullah, A;Ghauri, MA;Dai, B;Zhan, Y;Zhang, D;Zhang, Y;Year2019JournalCell Death DisApplicationELISAPubMed ID: 31819036FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
